Skip to main content
Premium Trial:

Request an Annual Quote

SNPs Long-Lost Companies Reassembled


Orchid BioSciences’ latest acquisition was a reunion of sorts. The company recently negotiated a stock deal to buy Lifecodes, whose niche is paternity and forensics genomic identity testing. Lifecodes owns the US division of Cellmark, which was split off from its original company about six years ago. The other part, Cellmark UK, was previously acquired by Orchid.

“We’ve been investing significantly in the next generation of technologies for looking at genetic diversity,” says Orchid CEO Dale Pfost, adding that the aim is pharmaceutical and healthcare applications of SNP scoring. The addition of Lifecodes, Orchid’s fourth acquisition, means the company now has “the critical mass to assemble Orchid Diagnostics,” Pfost says. With this unit and other Lifecodes assets, he expects the company’s overall revenue to double by next year to more than $50 million — $15 million is slated to come from the diagnostics unit alone.

— Meredith Salisbury

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.